Healthy Skepticism Library item: 10615

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: media release

Cegedim Strategic Data Releases Q1 Pharmaceutical Detailing & Spending Data
CEGEDIM Strategic Data 2007 Jun 20
http://sev.prnewswire.com/health-care-hospitals/20070620/NYW03120062007-1.html

Full text:

ENGLEWOOD CLIFFS, N.J., June 20 /PRNewswire/ — Cegedim Strategic Data, a leading Market Research company for the healthcare industry, publicly released select results from its quarterly pharmaceutical promotional detailing and spending database. The Q1 2007 numbers indicate GlaxoSmithKline (GSK), compared to competing manufactures, has the highest share of product details within the United States. GSK’s product detailing volume remained steady throughout the last four quarters, but its new first-place ranking is due to Pfizer’s decreased product detailing volume. Pfizer’s U.S. detailing volume decreased by 27% from the same period last year. Much of this decline can be attributed to Zoloft’s patent expiry, but Pfizer seems to be scaling back on its overall detailing activities and allocating more promotional funds to DTC advertising. Other companies in the top five, such as Novartis, Merck and Schering Plough, all experienced 14%-24% increases in overall detailing volume as compared to the same period last year.

Country: United States Panelists: PCP’s, Specialists & Pharmacists Total Detailing Manufacturer Product Detailing Volume Change Market Share Q1 2007 vs. Q1 2006 Rank 1 GLAXOSMITHKLINE -2% 2 PFIZER -27% 3 NOVARTIS 24% 4 MERCK & CO. 14% 5 SCHERING PLOUGH 17% 6 ASTRAZENECA -2% 7 ELI LILLY 18% 8 BOEHRINGER INGELHEIM 23% 9 SANOFI-AVENTIS -13% 10 BRISTOL MYERS SQUIBB -16%

Physicians & pharmacists report that diabetes-related products are the most heavily detailed medications during the quarter. In total, a projected 3.2 million diabetes-related product details were reported. This represents a 77% increase in the class when compared to Q1 2006. New product launches, such as Januvia & Exubera, contributed to this increase, as existing brands like GSK’s Avandia increased detailing efforts by 175% to protect its market share.

Cegedim Strategic Data will release its latest Diabetes Zoom Market Report on June 22, 2007. The syndicated report, using both qualitative and quantitative methodologies, will explore physician experiences and feedback to key product messages given by sales representatives. This version of the report will focus on the introduction of Januvia in the U.S., France, German, Italy, U.K., Spain & Japan.

CSD is a leading Market Research company dedicated to the healthcare industry and operating in more than 58 countries. With over 35 years experience in the pharmaceutical industry CSD (previously CAM, Thales, Zoom and Decisions Research) offers a comprehensive range of market research services and solutions to meet the needs of its customers, which include more than 50 global and 500 local Pharmaceutical companies. The capability to integrate primary market research with audited promotional data from PCPs, Specialists and Pharmacists, and merge it with longitudinal patient level data is what sets the company apart from its competition.

For more information, contact: Milena Brankova CEGEDIM Strategic Data 201-871-5913 milena.brankova@cegedim.com